If you notice any unusual or persistent symptoms, our team is here to evaluate and support you at every step
3.1 Tirzepatide effects: glucose lowering effects of tirzepatide Tirzepatide, a once-weekly subcutaneous injection, was FDA approved in May 2022 as an adjunct treatment with diet and exercise to improve glycemic control in adults with Type 2 diabetes [43]
Semaglutide (Wegovy/Ozempic) is the closest currently available alternative, producing 14-16% average weight loss compared to tirzepatide at 18-22%
Retatrutide has not received marketing authorisation from the MHRA or EMA and is not available through NHS prescribing pathways
Back Drucker, DJ, Holst, JJ (28 March 2023) 'The expanding incretin universe: from basic biology to clinical translation', Diabetologia , 66, 1765-29
Fluid and Pressure Control Lowers blood pressure through osmotic diuresis and natriuresis